news
AI targets protein linked to most human cancers
Scientists have used AI to design a molecule that disrupts a key protein interaction driving up to 70 percent of cancers - once thought impossible to drug.
List view / Grid view
Therapeutics
news
Engineering realistic blood vessels to fight vascular disease
Researchers at Texas A&M University have developed advanced vessel-chip technology that closely mimics the complex architecture of human blood vessels, offering a new potential platform for studying vascular diseases and accelerating drug discovery.
news
Experimental peptide targets glioblastoma’s most resilient cells
An experimental peptide from Virginia Tech may offer a new way to stop glioblastoma from coming back by disrupting the cancer’s treatment-resistant core.
article
Next-generation drug design: how generative AI can tackle undruggable targets
Generative AI is broadening the boundaries of what is possible in drug discovery. In this article, Murat Tunaboylu, CEO and Co-founder of Antiverse, reveals how the zeitgeist technology is enabling scientists to tackle previously undruggable targets like GPCRs and ion channels to deliver patient impact faster.
news
Herpes virus protein boosts T cell power against cancer
Researchers at the University of Michigan have engineered a herpes virus protein to enhance T cell survival and function, offering a new strategy to strengthen cancer immunotherapy.
article
Targeting GLP-1 in the brain could transform obesity care
What if a single hormone could control appetite in two entirely different ways? Professor Stefan Trapp of University College London reveals how GLP-1’s dual role in the brain and gut could transform obesity treatment.
article
Strategic planning in ADC development: insights from Lonza
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
news
Astrocyte protein RTP801 linked to Alzheimer’s cognitive decline
A new study from the University of Barcelona’s Institute of Neurosciences has discovered a crucial role for the RTP801 protein in astrocytes, potentially making way for future therapies aimed at slowing or reversing cognitive decline.
news
Why ATP signalling might change melanoma for good
A new study from Central South University reveals how adenosine phosphate signalling shapes the tumour microenvironment in melanoma, offering a new biomarker for guiding personalised cancer treatment.
news
New UCD centre targets the biggest bottleneck in rare research
The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.
article
New fixed-duration therapy could reshape CLL care
Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment…
news
Vascularised stem cell organoids advance diabetes therapy
A team of researchers have developed the first vascularised organoid model of human pancreatic islets, which could lead to further development of advanced cell therapies for diabetes.
article
Transforming cancer care through clinical excellence
Melika Davis at BeOne reflects on the inspiration and drive that has helped her forge a successful career in clinical operations.
news
Nasal spray gene therapy shows potential to treat lung diseases
Researchers at Mass General Brigham have developed a new gene therapy delivery system, AAV.CPP.16, that targets the lungs via nasal spray, which could offer a potential breakthrough in respiratory gene therapy.
article
Tackling complex manufacturing challenges in modern drug development
Chief Scientific Officer at Solvias reveals how CROs are overcoming manufacturing challenges and harnessing AI to fast-track the development of groundbreaking cell and gene therapies.
